North America Scar Treatment Market Size, Share, Growth and Forecast, 2025-2035

Clinic procedures take most of the spend

The North America scar treatment market was valued at USD 1.97 billion in 2025 and is projected to increase from USD 2.17 billion in 2026 to USD 4.81 billion by 2035, registering a CAGR of 9.25% during 2026–2035. Demand rests on acne patients seeking scar care, on surgical patients managing incisions, and on burn survivors who need long rehabilitation. The United States held 87.5% of regional value in 2025, reflecting the depth of its dermatology and plastic surgery practices and its large self-pay base. Mexico is the fastest-growing country at 10.25% a year, helped by a large aesthetic surgery workforce and rising specialist burn caseloads. Treatment choice is widening because the FDA cleared a nonablative laser for acne scarring across all Fitzpatrick skin types in April 2025, which widens the group of patients a clinic can treat with one device. However, most appearance-only care remains out of pocket, so pricing and clinic access continue to shape how quickly patients move from topicals to procedures.

What does scar treatment spending in North America include?

The market counts spending on topical silicone and botanical scar products, intralesional injections, surgical scar revision and laser and other energy-based sessions delivered for scars. Patients buy topicals directly from pharmacies and online stores, while procedures are bought through dermatology, plastic surgery and burn care practices. Clinic procedures account for most of the value in the Credence Research model, while topicals serve as the low-cost first step.

General anti-aging aesthetics, tattoo removal and acute wound dressings are excluded unless they are sold or used specifically for scars. The value chain runs from device and consumer brand owners through distributors and retailers to clinics, hospitals and the patients or payers who fund care.

Device procedures lead value and grow fastest

Why do device procedures lead and grow fastest?

Based on treatment type, the market is categorized into topical scar products, injectable scar treatments, surgical scar revision and device and adjunct procedures. Device and Adjunct Procedures led with 40.0% of 2025 value because laser work is a higher-value clinic service, and the International Society of Aesthetic Plastic Surgery estimated 101,497 full-field ablative procedures in the United States in 2024. Device and Adjunct Procedures also grow fastest at 10.03% a year as clearances widen eligibility, including the April 2025 FDA clearance of AVAVA Focal Point technology for acne scarring in Fitzpatrick skin types I to VI, as reported by MedPath.

Which scar causes generate the most spending?

Based on scar etiology, the market is categorized into post-surgical scars, post-acne scars, burn scars and traumatic scars. Post-Surgical Scars led with 42.0% of 2025 value because operative volume gives a steady base, with American Society of Plastic Surgeons members reporting 361,798 tumor removals in 2024. Post-Acne Scars grow fastest at 10.01% a year as the addressable pool is large, since the American Academy of Dermatology counts up to 50 million Americans with acne annually. Burn scars form a smaller but clinically intensive group that depends on specialist centers and long rehabilitation.

Where do patients receive scar care?

Based on care setting, the market is categorized into hospital-based care, specialist outpatient clinics and home-based care. Specialist Outpatient Clinics led with 62.0% of 2025 value because laser sessions are sold by office practices, while hospital scar work is concentrated, with the American Burn Association finding that 94 hospitals handled 81% of burn admissions. Home-Based Care grows fastest at 9.74% a year as Aetna requires a failed trial of silicone or paper tape before covering fractional laser, and Managed Healthcare Executive reported in September 2026 that more than 60% of U.S. counties have no dermatologist.

How do scar products and services reach patients?

Based on distribution channel, the market is categorized into retail pharmacy channels, digital commerce channels and professional care channels. Professional Care Channels led with 80.0% of 2025 value because procedures are only bought through practices, and Stratpharma offered its U.S. silicone gel through physicians when it entered the market in June 2017. Digital Commerce Channels grow fastest at 10.72% a year as online buying spreads, with the U.S. Census Bureau reporting that e-commerce reached 17.1% of retail sales in the second quarter of 2026.

Acne, surgery and laser capacity set the pace of demand

Acne patients are converting into scar-treatment buyers

Conversion of acne patients into scar-treatment buyers is the largest source of new demand because the pool of potential patients is so large. The American Academy of Dermatology states that acne affects up to 50 million Americans annually, while a 2022 Canadian Skin Patient Alliance survey with 154 responses found 87% reporting scarring, although that sample was not population-representative. Clinical evidence is also easing the decision for darker skin types, since MedPath reported in April 2025 that a 47-subject AVAVA study, in which 75% identified as African American, Asian or Hispanic/Latino, showed a 50% median reduction in scar severity. As a result, Post-Acne Scars are projected to expand at 10.01% a year through 2035.

Post-surgical scar management follows reconstructive volume

Post-surgical scar management grows with the volume of operations, because every incision creates a potential buyer of silicone sheeting or later revision. American Society of Plastic Surgeons data for 2024 show members performing 1,048,534 reconstructive procedures, up 2% from 2023, including 54,280 scar revisions, up 4%. Those counts cover members only, which is why the International Society of Aesthetic Plastic Surgery estimate of 190,854 U.S. surgical scar revisions in 2024 is far higher. Suppliers are positioned for this demand, as Smith+Nephew keeps its Cica-Care silicone gel sheet in U.S. commercial distribution under FDA product code MDA, a category bought alongside advanced wound dressings by surgical practices. In turn, post-surgical scars held 42.0% of 2025 spending in this regional market.

Download Free Sample

Specialist laser capacity is expanding across the region

Specialist laser capacity lifts spending because scar remodeling can only be sold where trained operators and suitable devices are available. The International Society of Aesthetic Plastic Surgery survey estimated 101,497 full-field ablative procedures in the United States and 15,530 in Mexico during 2024. Device makers are adding to that installed base, as Cynosure Lutronic promoted its 1550 nm Mosaic 3D fractional laser for tone and texture in October 2024 and sells directly in the United States and Canada, and Candela obtained Health Canada licenses in February 2023 for Frax 1550 applicators that treat acne and surgical scars. These platforms are used across other aesthetic energy devices, so a clinic can justify the purchase on several indications. Consequently, Device and Adjunct Procedures are forecast to rise at 10.03% a year.

Burn survivors create long-duration rehabilitation demand

Burn injuries add a smaller but durable stream of demand, because scar care continues well after the acute hospital stay ends. The American Burn Association fact sheet cites 398,000 fire or burn injuries in 2021 and 29,165 U.S. burn admissions a year on 2020 data, with 94 hospitals handling 81% of admissions. Mexico shows similar pressure, since the Mexican Social Security Institute said in May 2026 that pediatric burn cases at its national referral hospital rose from 217 in 2024 to 332 in 2025. Payers also recognize this need more readily than appearance care, as Aetna covers fractional ablative laser for burn scars with documented functional impairment. This keeps specialist burn units and rehabilitation teams as steady buyers.

Nonablative lasers and new ownership reshape supply

A shift toward nonablative lasers for all skin types

Clinics are shifting toward nonablative scar lasers because devices cleared for all skin types with short recovery widen the patient base. MedPath reported that AVAVA gained FDA clearance for Focal Point technology in April 2025 covering Fitzpatrick types I to VI, with an average reported pain score of 3 out of 10 and mild redness typically resolving in one to two days. The same direction appears in Cynosure Lutronic's Mosaic 3D, a 1550 nm erbium glass nonablative fractional laser promoted in October 2024 for tone and texture, and in Candela's Frax Pro platform, licensed by Health Canada in February 2023. As a result, post-acne work is the fastest-growing scar cause in the Credence Research model for this regional market through 2035.

Rising private ownership is reshaping the supplier base

Ownership of leading scar brands and laser makers is moving into private hands, which changes how suppliers fund launches and clinic support. U.K. Investor Magazine reported in March 2022 that Perrigo sold ScarAway to Alliance Pharma, together with U.S. rights to Kelo-cote, for $19.4 million in cash. Alliance itself agreed on March 28, 2025 to a £349.7 million takeover by DBAY Advisors, its largest shareholder, according to Sharecast. Cutera emerged from Chapter 11 in May 2025 as a private company after cutting debt by nearly $400 million and raising $65 million from its lenders, according to its own release. Cynosure and Lutronic had already combined in 2024, so clinic buyers now deal with vendors whose owners and funding have changed.

Download Free Sample

Opportunity in home-first care where specialists are scarce

Home-first care offers a clear opening because large areas of the region lack a nearby specialist. Managed Healthcare Executive reported in September 2026 that the United States has 3.4 dermatologists per 100,000 people and that only about 10% practice in rural areas. The Canadian Dermatology Association puts Canada at about 1.9 per 100,000 in 2023, with Saskatchewan at 0.7 and a shortfall of 465 against its target ratio. Online buying can close part of this gap, since U.S. Census Bureau data put e-commerce at 17.1% of retail sales in the second quarter of 2026. Brands that pair silicone products with remote guidance could therefore capture patients before any clinic visit, and Digital Commerce Channels are forecast to grow at 10.72% a year.

Opportunity in Mexico's large surgeon and procedure base

Mexico offers an opening for device makers and clinic groups because its aesthetic workforce is large relative to its share of regional value. The International Society of Aesthetic Plastic Surgery estimated 1,294,946 procedures in Mexico in 2024, with 1,991 plastic surgeons and 32,254 surgical scar revisions. Public capacity for severe cases is concentrated, as La Razón reported in September 2025 that the National Rehabilitation Institute burn service has 20 subacute beds and two operating rooms. That concentration leaves room for private outpatient scar programs in other cities. As a result, Mexico is the fastest-growing country in this report, even though it held only 5.7% of 2025 regional value.

Coverage limits and specialist shortages restrain uptake

Insurers limit laser coverage to functional impairment

Limited coverage is the main brake on procedure spending because most patients must pay themselves. A January 2025 study in the Journal of Burn Care & Research found that 37.2% of 60 major U.S. insurers considered laser therapy medically necessary, typically only with documented functional impairment. Cigna's policy effective June 15, 2026 treats revision done solely for appearance as cosmetic. Clinics can respond with package pricing and financing, although patients without savings may remain with lower-cost topicals.

Evidence gaps weaken payer and buyer confidence

Thin evidence makes it harder for clinics and payers to justify higher-priced care. Canada's CADTH concluded in its June 24, 2019 review of fractionated CO2 laser for burn scars that the evidence was of limited quality and found no cost-effectiveness data. Similarly, Aetna's policy reviewed May 28, 2026 lists silicone gel and sheeting as unproven for hypertrophic scars and keloids. Manufacturers can reduce this barrier by funding larger controlled trials with functional outcomes.

Specialist waits delay procedures for many patients

Scarce specialist time delays treatment and caps procedure volume, especially outside large cities. AMN Healthcare found in its 2025 physician survey that dermatology appointments took an average of 36.5 days across 15 metro areas, up 6% since 2022. The strain is sharper in Canada, where the Canadian Dermatology Association reports a shortfall against its target ratio. Practices can offset part of this by delegating device sessions to trained staff under physician supervision, where provincial and state rules allow.

Trade policy could raise imported device and dressing costs

Trade policy adds cost uncertainty because the U.S. review reaches imported products used in scar care. The Commerce Department began a Section 232 investigation on Sept. 2, 2025 covering medical consumables, equipment and devices, with comments due Oct. 17, 2025, and SPS Commerce reported on Oct. 28, 2026 that no report, proclamation or tariff had followed. Any later tariff would fall first on importers and then on clinics buying capital equipment. Suppliers could therefore consider domestic assembly and longer contracts to protect margins and patient prices.

The United States dominates, and Mexico grows quickest

United States anchors spending through private-pay clinics

The United States held 87.5% of 2025 value and grows at 9.15% a year because it combines a large clinic base with patients who pay directly for appearance care. The International Society of Aesthetic Plastic Surgery estimated 6,165,173 aesthetic procedures and 7,752 plastic surgeons in this largest regional market in 2024. However, access is uneven, since Managed Healthcare Executive reported an average wait of about 32.3 days to see a dermatologist in September 2026.

Canada grows from a small base with few dermatologists

Canada held 6.8% of 2025 value and grows at 9.65% a year, with demand tied to a thin specialist base of about 750 registered dermatologists in 2023. The Canadian Skin Patient Alliance states that acne affects about 20% of Canadians, which supports a sizable post-acne demand pool. Cynosure Lutronic also gained Health Canada clearance for its XERF skin tightening device in April 2025, four months before its U.S. clearance, which adds to its Canadian clinic offer.

Download Free Sample

Mexico expands fastest through aesthetic and burn demand

Mexico held 5.7% of 2025 value and grows at 10.25% a year, the fastest pace in the region, because a large surgical workforce is building from a small share of regional spending. The International Society of Aesthetic Plastic Surgery estimated 560,865 nonsurgical aesthetic procedures in Mexico in 2024, which indicates clinic demand beyond surgery. Burn care adds a further need, as the Mexican Social Security Institute reported a sharp rise in specialist pediatric cases in its May 2026 bulletin.

Download Free Sample

Clearances and restructurings marked 2025

Four treatment mechanisms compete for each scar type

• Silicone occlusion places a silicone sheet or gel over the scar, and FDA device records list Smith+Nephew Cica-Care under product code MDA as an elastomer for scar management.
• Pharmacologic therapy uses intralesional corticosteroids or 5-fluorouracil, which Aetna treats as medically necessary for keloids when its removal criteria are met.
• Energy-based remodeling applies laser energy to scar tissue, and Candela states that its Frax 1550 applicators treat acne scars, surgical scars and striae.
• Mechanical revision covers excision and abrasion, although Cigna's 2026 policy treats superficial abrasion for scar revision as not medically necessary.

Consumer brands and laser makers compete in separate lanes

Competition in the region runs in three commercial lanes that rarely overlap. Consumer and pharmacy brands compete on price, shelf presence and word of mouth, with Perrigo behind Mederma and Alliance Pharma behind ScarAway and U.S. Kelo-cote. Clinical silicone suppliers such as Smith+Nephew, Mölnlycke Health Care, Stratpharma and Newmedical Technology sell through surgeons, hospitals and dermatology practices, where clinical familiarity and supply contracts matter more than advertising. Device makers including Cynosure Lutronic, Candela, Lumenis and Cutera compete for clinic capital budgets, so they stress multi-indication platforms and practice training rather than scars alone. Newer entrants such as AVAVA are pressing on skin-type coverage as a point of difference. Financial structure now also matters, since Cutera's restructuring and the Alliance takeover both changed owners during 2025. Scale in clinic service and training support is likely to decide share among device vendors over the forecast period.

Companies profiled and their roles in this market

Device-led acne care should outrun the topical base

Credence Research's view is that device-led acne care will outrun the topical base through 2035, because new clearances for darker skin types remove a long-standing limit on who can be treated. Even so, topicals keep a lasting role because they remain the cheapest first step and need no appointment. The main risk is that specialist capacity does not keep pace, particularly in Canada and rural U.S. counties. Vendors that combine training with financing for clinics are therefore better placed than those competing on device specifications alone. Growth at 9.25% a year assumes coverage rules stay broadly stable.

Public clinical and procedure data feed the model

The report uses 2025 as the base year and forecasts to 2035. Market values come from the Credence Research model, and segment and country splits are Credence Research estimates checked against public procedure, burn and workforce data. Sources include professional society statistics, U.S. government data, payer policies, company releases and peer-reviewed literature opened during research. No primary interviews or surveys were conducted for this edition.

Procedure access will decide the market through 2035

The market is projected to reach USD 4.81 billion by 2035, with procedure access deciding how far spending moves beyond topicals. Post-acne care should gain the most as nonablative lasers spread into general dermatology practices. Canada will depend on how quickly it trains more dermatologists, while Mexico should keep building private outpatient programs in its larger cities. Trade policy remains the main external unknown for device pricing. As a result, companies that secure clinic relationships and home-care reach early should hold an advantage through the end of the forecast period.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.